| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 47.169 | 53.793 | 52.645 | 25.548 | 0 | 0 | 0 | 502 | 0 | 0 |
| Total Income - EUR | 47.409 | 53.818 | 52.651 | 25.551 | 0 | 0 | 0 | 502 | 0 | 0 |
| Total Expenses - EUR | 19.849 | 17.288 | 20.502 | 9.479 | 5.343 | 709 | 743 | 3.028 | 1.695 | 890 |
| Gross Profit/Loss - EUR | 27.560 | 36.530 | 32.149 | 16.072 | -5.343 | -709 | -743 | -2.526 | -1.695 | -890 |
| Net Profit/Loss - EUR | 26.138 | 34.915 | 30.569 | 15.604 | -5.343 | -709 | -743 | -2.541 | -1.695 | -890 |
| Employees | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Mcn Pharma Consulting Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 281 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 150.220 | 170.685 | 200.130 | 204.215 | 191.371 | 187.498 | 182.662 | 13.023 | 13.254 | 8.913 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 120.581 | 130.130 | 199.069 | 204.184 | 191.368 | 187.478 | 182.653 | 13.014 | 13.245 | 8.904 |
| Cash | 29.640 | 40.556 | 1.061 | 31 | 2 | 20 | 9 | 9 | 9 | 9 |
| Shareholders Funds | 134.273 | 34.968 | 30.622 | 15.656 | 10.010 | 9.111 | 8.165 | 5.649 | 3.937 | 3.025 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 15.598 | 135.717 | 168.419 | 188.027 | 180.840 | 177.876 | 173.997 | 7.374 | 9.317 | 5.888 |
| Income in Advance | 630 | 445 | 1.089 | 532 | 522 | 512 | 500 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7022 - 7022" | |||||||||
| CAEN Financial Year |
7490
|
|||||||||
Comments - Mcn Pharma Consulting Srl